Inhibitory processes are ubiquitous within the nervous system and play essential roles in the regulation of neural activity and neural plasticity. Within the brain, inhibition is mediated predominantly by gamma amino butyric acid (GABA), a neurotransmitter that activates several receptor types. Consistent with inhibitory models of rivalry alternations, recent research has demonstrated that short-term, monocular eye patching temporarily affects the subsequently measured temporal dynamics of dominance in favor of the previously patched eye and, at the same time, decreases GABA concentrations in the occipital cortex (Lunghi, Emir, Morrone, & Bridge,
2015). A possible relationship between GABA and perceptual rivalry alternations is also suggested by increased durations of rivalry dominance induced pharmacologically by lorazepam, a GABA
A agonist (van Loon et al.,
2013). From an individual differences perspective, individuals with greater resting concentrations of GABA in the occipital cortex exhibit longer durations of perceptual dominance in rivalry (van Loon et al.,
2013). These correlations between GABA levels and rivalry dynamics suggest that binocular rivalry may provide a reliable proxy for GABA concentrations in the human brain. If so, given prior evidence indicating atypical patterns of rivalry dynamics linked to schizophrenia (Tononi & Edelman,
2000) and autism (Freyberg, Robertson, & Baron-Cohen,
2015; Robertson, Kravitz, Freyberg, Baron-Cohen, & Baker,
2013), the linkage between GABA and rivalry might promote investigations of the neurochemical and inhibitory imbalances associated with these disorders. However, the evidence for atypical rivalry dynamics linked to these conditions is not uniformly consistent (Miller et al.,
2003; Said, Egan, Minshew, Behrmann, & Heeger,
2013), suggesting that the relation between GABA and perceptual alternations may be more nuanced and thus require further consideration. Toward that end, we have taken a different approach to the study of this putative relationship, one based on endogenous neuropharmacological changes in ovulating females.